Moxifloxacin is the first drug of the company registered in Singapore
In May of this year, Moxifloxacin (solution for infusion) manufactured by Galichpharm received official registration in Singapore. This is another important step towards expanding the global presence of Ukrainian medicinal products of Arterium TM. Further plans include registration of another product, Magnesium sulfate 50% (solution for injection).
High requirements - high level
Maria Kovaleva, Medicines Registration Manager, says: Moxifloxacin was registered according to the requirements of the HSA (Health Sciences Authority). This is the national regulatory authority of Singapore, known for its high standards of quality, safety and efficacy of medicines.
"We have gained extremely valuable experience, as one of the requirements of the HSA is to prepare registration documents in the CTD (Common Technical Document) format. This format is used by the world's leading regulators, including the EU and the US. Therefore, this is the experience we take with us into the future. At the same time, the fact of registration is a confirmation of the existing high level of quality of our documentation," says Maria.
A prerequisite for registration was also confirmation of compliance with GMP standards. Earlier, we reported that the company's ampoule and infusion lines had passed the relevant assessment. This is an international recognition of Galichpharm's qualifications as a manufacturer.
What are the product's market prospects
From the beginning of 2026, Moxifloxacin will participate in hospital procurement in Singapore. Hospitals in this country, especially in intensive care and surgery departments, have a steady demand for broad-spectrum antibiotics, including Moxifloxacin. It is used to treat community-acquired pneumonia and complicated infectious diseases of the skin and subcutaneous tissues.
Another advantage of our product is its convenient dosage form. Singaporean hospitals are increasingly preferring “ready-to-use” formulations: Moxifloxacin in the form of a ready-to-use infusion solution is in line with this trend and is an alternative to powders that require pre-dilution.